Inhibitors of thrombin induced platelet aggregation
AssigneeParker Hughes Institute
InventorFaith M. Uckun
Life of this patent
Estimating the term…
Abstract
The present invention describes a therapeutic method useful for treating or preventing a condition of platelet aggregation in a subject including administering a pharmaceutically effective amount of a compound or composition that inhibits JAK-3 and/or tyrosine phosphorylation of STAT-3 and inhibits thrombin induced platelet aggregation. The condition of platelet aggregation includes hematopoietic and cerbrovascular diseases.
Claims7
A method for treating a disease or condition characterized by platelet aggregation comprising administering a pharmaceutically effective amount of a JAK-3 inhibitor, wherein the YAK-3 inhibitor inhibits tyrosine phosphorylation of STAT-3.
A method for selectively inhibiting thrombin-induced platelet aggregation comprising administering to said platelets a JAK-3 inhibitor.
A method for selectively inhibiting thrombin-induced platelet aggregation comprising administering to said platelets a JAK-3 inhibitor represented by formula I:
- wherein:
- X is selected from the group consisting of HN, R11N, S, O, CH2, and R11CH;
- R11 is (C1-C4)alkyl or (C1-C4)alkanoyl;
- R1-R5 are each independently selected from the group consisting of hydrogen, hydroxy, and halo where at least one of R1-R5 is hydroxy;
- R6, R7, and R8 are each independently selected from the group consisting of hydrogen, hydroxy, mercapto, amino, nitro, (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)alkylthio, and halo;
- and
- R9 and R10 are each independently selected from the group consisting of hydrogen, (C1-C4)alkyl, (C1-C4)alkoxy, halo, and (C1-C4)alkanoyl;
- or R9 and R10 together are methylenedioxy;
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.